Clinical Trials
29 trialsCOVID-19 Testing in Underserved and Vulnerable Populations
University of California, San Diego
WAVe
Ottawa Hospital Research Institute
MK-7962-012
Merck Sharp & Dohme LLC
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Amgen
A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia
University of Pittsburgh
Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
AIO-Studien-gGmbH
Role of Virtual Reality (VR) in Patients With Sickle Cell Disease (SCD)
Duke University
Ilera
Children's Hospital of Philadelphia
CANDLE-KIT
CANDLE-KIT Trial Study Group
DALFEN
All India Institute of Medical Sciences
ALICAT
Cardiff University
Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer
Forest Laboratories
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
University of Southern California
RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia
Ortho Biotech Products, L.P.
Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer
University of Aarhus
Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers
City of Hope Medical Center
Longheva
University Medical Center Groningen
HaemOPtimal
Rigshospitalet, Denmark
Darbepoetin Alfa and Anemia of Cancer
Amgen
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients
Alberta Children's Hospital
The Duration Study
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.
Ortho Biotech Products, L.P.
A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Trousseau
Slotervaart Hospital
A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy
Amgen
Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced
Institut Claudius Regaud
Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care
University Hospital, Geneva